Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 10, 2025 (12 months ago)

HADLIMA (adalimumab-bwwd)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.

Affected NDC 78206-0183-01

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Hadlima
adalimumab-bwwd
NDC 78206-0183
ADALIMUMAB 40 mg/.8mL Solution
Subcutaneous
Organon LLC Rx
Recalling firm
Samsung Bioepis Co., Ltd.
NDC code
78206-183-01
Origin
N/A, Korea (the Republic of)
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0099-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other sterility / contamination recalls from 2025

All sterility / contamination recalls
Class II · Moderate risk

Vista Gonio Eye Lubricant

Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

Ongoing Sterility / contamination Wizcure Pharmaa Private Limited NDC 77790-022-15 D-0349-2026